A-101 25%
A-101-SEBK-201
Phase 2 small_molecule completed
Quick answer
A-101 25% for Seborrheic Keratosis (SK) is a Phase 2 program (small_molecule) at Aclaris Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Aclaris Therapeutics
- Indication
- Seborrheic Keratosis (SK)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed